ClinicalTrials.gg

Program

hydronidone

Also written as “Hydronidone capsules”, “Hydronidone” and “[¹⁴C]Hydronidone”.

Its studies are mostly in Liver Cirrhosis · Hepatitis B, Chronic · Renal Insufficiency, Chronic · Hepatitis B, led by 2 companies.

Furthest: phase 3, since Oct 9, 202115 company-led studies, 3 open or runningNext primary completion: Dec 1, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GNI Group143 open or runningphase 3since Oct 9, 2021Oct 9, 2019Dec 1, 2026phase 1 · NCT07262333
Shanghai Genomics10 open or runningphase 2since Jun 26, 2015Jun 26, 2015none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 26, 2015First study: phase 2 study in Hepatitis B, ChronicNew to Shanghai GenomicsShanghai Genomics · NCT02499562 · 168 enrolled · China
  2. Oct 9, 2019GNI Group's first study: no phase study in HealthyNew to GNI GroupGNI Group · NCT04125056 · 40 enrolled · China
  3. Oct 10, 2019Phase 1 study in Hepatitis BGNI Group · NCT04123769 · 8 enrolled · China
  4. Nov 12, 2019Phase 1 study in Pharmacokinetics of HydronidoneGNI Group · NCT04162821 · 48 enrolled · China
  5. Oct 9, 2021Phase 3 study in Liver CirrhosisGNI Group · NCT05115942 · 248 enrolled · China
  6. Jun 7, 2023Phase 3 study in Liver CirrhosisGNI Group · NCT05905172 · 248 planned · China
  7. Nov 17, 20253 phase 1 studiesGNI Group · NCT07262346, NCT07262333, NCT07263152
  8. Jan 7, 20262 phase 3 studiesGNI Group · NCT07343778, NCT07412236
  9. Jan 16, 2026Phase 2 study in Chronic Hepatitis B With Hepatic FibrosisGNI Group · NCT07364448 · 411 enrolled · China
  10. Jan 30, 2026Phase 1 study in Liver CirrhosisGNI Group · NCT07394309 · 30 enrolled · China
  11. Feb 11, 2026Phase 2 study in Chronic Hepatitis B-related Liver FibrosisGNI Group · NCT07417553 · 67 enrolled · China
  12. Mar 10, 2026Phase 1 study in Chronic Hepatitis B-related Liver FibrosisGNI Group · NCT07471217 · 6 enrolled · China

Ahead

  1. Dec 1, 2026Primary completion: phase 1 study in Renal Insufficiency, ChronicGNI Group · NCT07262333
  2. Jun 20, 2028Primary completion: phase 3 study in Liver CirrhosisGNI Group · NCT05905172
  3. Dec 30, 2028Primary completion: phase 3 study in Liver CirrhosisGNI Group · NCT07412236

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07471217Chronic Hepatitis B-related Liver Fibrosis · China1CompletedGNI GroupMay 6, 20266
NCT07417553Chronic Hepatitis B-related Liver Fibrosis · China2CompletedGNI GroupJul 27, 202667
NCT07394309Liver Cirrhosis · China1CompletedGNI GroupMay 11, 202630
NCT07412236Liver Cirrhosis · China3Not yet recruitingGNI GroupDec 30, 20281,208
NCT07364448Chronic Hepatitis B With Hepatic Fibrosis · China2CompletedGNI GroupJun 22, 2026411
NCT07343778Chronic Hepatitis B With Hepatic Fibrosis · China3CompletedGNI GroupJul 28, 2026337
NCT07263152Liver Cirrhosis · China1CompletedGNI GroupFeb 9, 202648
NCT07262346Liver Cirrhosis · China1CompletedGNI GroupMay 28, 2026138
NCT07262333Renal Insufficiency, Chronic · China1RecruitingGNI GroupDec 1, 202656
NCT05905172Liver Cirrhosis · China3RecruitingGNI GroupJun 20, 2028248
NCT05115942Liver Cirrhosis · China3CompletedGNI GroupOct 22, 2024248
NCT04162821Pharmacokinetics of Hydronidone · China1CompletedGNI GroupNov 27, 201948
NCT04123769Hepatitis B · China1CompletedGNI GroupOct 9, 20208
NCT04125056Healthy · China–CompletedGNI GroupJan 23, 201940
NCT02499562Hepatitis B, Chronic · China2CompletedShanghai GenomicsNov 20, 2020168

How it is read

Names in the registry

  • “Hydronidone capsules”, 7 entries
  • “Hydronidone”, 4 entries
  • “[¹⁴C]Hydronidone”, 1 entry
  • “Hydronidone Capsules”, 1 entry
  • “Hydronidone (270mg)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.